HCW Biologics Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| Years EndedDecember 31, | ||
|---|---|---|
| 2022 | 2023 | |
| Revenues: | ||
| Revenues | $6,722,090 | $2,841,794 |
| Cost of revenues | (4,135,712) | (2,281,434) |
| Net revenues | 2,586,378 | 560,360 |
| Operating expenses: | ||
| Research and development | 9,338,365 | 7,676,316 |
| General and administrative | 8,326,791 | 13,351,204 |
| Reserve for credit losses | — | 5,250,000 |
| Total operating expenses | 17,665,156 | 26,277,520 |
| Loss from operations | (15,078,778) | (25,717,160) |
| Interest expense | (126,660) | (283,042) |
| Other (expense) income, net | 304,735 | 1,005,925 |
| Net loss | $(14,900,703) | $(24,994,277) |
| Net loss per share, basic and diluted | $(0.42) | $(0.70) |
| Weighted average shares outstanding, basic and diluted | 35,822,249 | 35,929,446 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.